Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile

Simple item page
dc.article.number1101526
dc.catalogadoraba
dc.contributor.authorLe Corre, Nicole
dc.contributor.authorAbarca Villaseca, Katia
dc.contributor.authorAstudillo, Patricio André
dc.contributor.authorPotin Santander, Marcela Patricia
dc.contributor.authorLópez, Sofía
dc.contributor.authorGoldsack, Macarena
dc.contributor.authorValenzuela Guerrero, Vania
dc.contributor.authorSchilling Redlich, Andrea
dc.contributor.authorGaete, Victoria
dc.contributor.authorRubio, Lilian
dc.contributor.authorCalvo, Mario
dc.contributor.authorTwele, Loreto
dc.contributor.authorGonzález, Marcela
dc.contributor.authorFuentes, Daniela
dc.contributor.authorGutiérrez Muñoz, Valentina José
dc.contributor.authorReyes Zaldivar, Felipe Tomás
dc.contributor.authorTapia, Lorena I.
dc.contributor.authorVillena, Rodolfo
dc.contributor.authorRetamal Díaz, Angello
dc.contributor.authorCárdenas, Antonio
dc.contributor.authorAlarcón Bustamante, Eduardo
dc.contributor.authorXin, Qianqian
dc.contributor.authorGonzález Aramundiz, José Vicente
dc.contributor.authorÁlvarez Figueroa, María Javiera
dc.contributor.authorGonzález Muñoz, Pablo Alberto
dc.contributor.authorBueno Ramírez, Susan
dc.contributor.authorSoto Ramírez, Jorge Andrés
dc.contributor.authorPerret Pérez, Cecilia
dc.contributor.authorMeng, Xing
dc.contributor.authorKalergis Parra, Alexis Mikes
dc.date.accessioned2023-10-04T19:59:47Z
dc.date.available2023-10-04T19:59:47Z
dc.date.issued2023
dc.description.abstractDuring the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.
dc.fechaingreso.objetodigital2023-10-04
dc.fuente.origenORCID
dc.identifier.doi10.3390/vaccines11101526
dc.identifier.urihttps://www.mdpi.com/2076-393X/11/10/1526
dc.identifier.urihttps://doi.org/10.3390/vaccines11101526
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/75011
dc.identifier.wosidWOS:001097881500001
dc.information.autorucEscuela de Medicina; Le Corre Perez, Monique Nicole; 0000-0002-9361-4049; 6737
dc.information.autorucEscuela de Medicina; Abarca Villaseca, Katia; 0000-0003-0404-3887; 70281
dc.information.autorucEscuela de Medicina; Potin Santander, Marcela Patricia; 0000-0003-4985-4579; 64027
dc.information.autorucEscuela de Medicina; Goldsack, Macarena; S/I; 182409
dc.information.autorucEscuela de Química y Farmacia; Álvarez Figueroa, María Javiera; 0000-0001-5911-7543; 70358
dc.information.autorucFacultad de Ciencias Biológicas; Bueno Ramírez, Susan; 0000-0002-7551-8088; 113541
dc.information.autorucEscuela de Medicina; Perret Pérez, Cecilia; 0000-0002-1535-1204; 80387
dc.information.autorucEscuela de Medicina; Astudillo, Patricio André; 0000-0002-2600-630X; 179203
dc.information.autorucEscuela de Medicina; Valenzuela Guerrero, Vania; S/I; 218616
dc.information.autorucEscuela de Medicina; Gutiérrez Muñoz, Valentina José; 0000-0002-5815-5035; 227663
dc.information.autorucEscuela de Medicina; Reyes Zaldivar, Felipe Tomás; 0000-0002-8980-8158; 237969
dc.information.autorucEscuela de Química y Farmacia; González Aramundiz, José Vicente; 0000-0001-7856-9211; 17164
dc.information.autorucFacultad de Ciencias Biológicas; González Muñoz, Pablo Alberto; 0000-0001-7709-6870; 15616
dc.information.autorucFacultad de Ciencias Biológicas; Soto Ramírez, Jorge Andrés; 0000-0003-0335-9759; 237269
dc.information.autorucEscuela de Medicina; Kalergis Parra, Alexis Mikes; 0000-0001-7622-5263; 90610
dc.issue.numero10
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final13
dc.pagina.inicio1
dc.revistaVaccines
dc.rightsacceso abierto
dc.subjectCoronaVac®
dc.subjectSARS-CoV-2
dc.subjectCOVID-19 vaccines
dc.subjectInactivated virus vaccine
dc.subjectSafety pattern
dc.subjectChildren
dc.subjectAdolescents
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleDifferent Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile
dc.typeartículo
dc.volumen11
sipa.codpersvinculados6737
sipa.codpersvinculados70281
sipa.codpersvinculados64027
sipa.codpersvinculados182409
sipa.codpersvinculados70358
sipa.codpersvinculados113541
sipa.codpersvinculados80387
sipa.codpersvinculados179203
sipa.codpersvinculados218616
sipa.codpersvinculados227663
sipa.codpersvinculados237969
sipa.codpersvinculados17164
sipa.codpersvinculados15616
sipa.codpersvinculados237269
sipa.codpersvinculados90610
sipa.trazabilidadORCID;2023-10-02
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vaccines-11-01526.pdf
Size:
0 B
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas